TR200102845T2 - Kanserlerin iyileştirilmesi için RHUMAB HER2 ile birlikte dosetaksel - Google Patents

Kanserlerin iyileştirilmesi için RHUMAB HER2 ile birlikte dosetaksel

Info

Publication number
TR200102845T2
TR200102845T2 TR2001/02845T TR200102845T TR200102845T2 TR 200102845 T2 TR200102845 T2 TR 200102845T2 TR 2001/02845 T TR2001/02845 T TR 2001/02845T TR 200102845 T TR200102845 T TR 200102845T TR 200102845 T2 TR200102845 T2 TR 200102845T2
Authority
TR
Turkey
Prior art keywords
heal
docetaxel
cancers
rhumab her2
her2
Prior art date
Application number
TR2001/02845T
Other languages
English (en)
Inventor
E. Bellet Robert
Original Assignee
Aventis Pharma S.A.
Charles L. Vogel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22435924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200102845(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma S.A., Charles L. Vogel filed Critical Aventis Pharma S.A.
Publication of TR200102845T2 publication Critical patent/TR200102845T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Drying Of Gases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Bu bulus, kanserin iyilestirilmesinde kullanima yönelik antineoplastik maddelerin bir yeni terapötik ve sinerjistik kombinasyonuna iliskindir. Bu bulus, daha özel olarak ise, kanserlerin iyilestirilmesi için rekombinant insan kullanimina uygun hale getirilmis anti-HER2 antikoru, rhuMAb HER2 ile birlikte dosetakselin kullanimina iliskindir.
TR2001/02845T 1999-04-09 2000-04-07 Kanserlerin iyileştirilmesi için RHUMAB HER2 ile birlikte dosetaksel TR200102845T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12856499P 1999-04-09 1999-04-09

Publications (1)

Publication Number Publication Date
TR200102845T2 true TR200102845T2 (tr) 2002-01-21

Family

ID=22435924

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02845T TR200102845T2 (tr) 1999-04-09 2000-04-07 Kanserlerin iyileştirilmesi için RHUMAB HER2 ile birlikte dosetaksel

Country Status (22)

Country Link
US (1) US6333348B1 (tr)
EP (1) EP1169059B1 (tr)
JP (2) JP2003512298A (tr)
KR (1) KR100695383B1 (tr)
CN (1) CN1191859C (tr)
AT (1) ATE307608T1 (tr)
AU (1) AU777661B2 (tr)
BR (1) BR0009647A (tr)
CA (1) CA2368369C (tr)
CZ (1) CZ296373B6 (tr)
DE (1) DE60023476T2 (tr)
DK (1) DK1169059T3 (tr)
EA (1) EA006097B1 (tr)
ES (1) ES2248070T3 (tr)
HK (2) HK1043313A1 (tr)
HU (1) HU226672B1 (tr)
MX (1) MXPA01010138A (tr)
NO (1) NO332619B1 (tr)
NZ (1) NZ515337A (tr)
TR (1) TR200102845T2 (tr)
WO (1) WO2000061185A1 (tr)
ZA (1) ZA200107771B (tr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AU771224B2 (en) 1998-07-13 2004-03-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6406693B1 (en) * 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
AU750414B2 (en) * 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP4579471B2 (ja) * 1999-06-25 2010-11-10 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
GB9917012D0 (en) * 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
PL202369B1 (pl) 1999-08-27 2009-06-30 Genentech Inc Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało
CN1447696A (zh) * 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
WO2002041914A1 (en) * 2000-11-21 2002-05-30 Cell Pathways, Inc. Method for treating neoplasia by administering an anti-her2 antibody and a cgmp-specific phosphodiesterase inhibitor
EP1353693B1 (en) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
LT2762140T (lt) 2001-02-19 2017-06-26 Novartis Ag Solidinių smegenų navikų gydymas rapamicino dariniu
EP1390078A4 (en) * 2001-04-26 2005-10-26 Analogic Corp CT SCANNER FOR THE PRESENTATION OF A PARTICULARLY FIXED PART OF A PATIENT
WO2003062375A2 (en) * 2001-12-19 2003-07-31 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
GB0200657D0 (en) * 2002-01-12 2002-02-27 Antisoma Plc Cancer treatment
US7247303B2 (en) * 2002-07-15 2007-07-24 Board Of Regents, The University Of Texas System Selected antibody CDRs for binding to aminophospholipids
US7678386B2 (en) * 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
US7622118B2 (en) * 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7572448B2 (en) * 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Combined cancer treatment methods using selected antibodies to aminophospholipids
US7572442B2 (en) * 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Selected antibody compositions for binding to aminophospholipids
US7714109B2 (en) * 2002-07-15 2010-05-11 Board Of Regents, The University Of Texas System Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
US7625563B2 (en) * 2002-07-15 2009-12-01 Board Of Regents, The University Of Texas System Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
US7615223B2 (en) * 2002-07-15 2009-11-10 Board Of Regents, The University Of Texas System Selected immunoconjugates for binding to aminophospholipids
WO2004048525A2 (en) * 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
ES2710439T3 (es) 2005-01-21 2019-04-25 Genentech Inc Dosificación fija de anticuerpos HER
BRPI0606557A2 (pt) * 2005-02-09 2009-06-30 Genentech Inc método de inibição do abrigo de her2, método de redução do nìvel em soro de domìnio extracelular (ecd) de her2 em mamìferos, métodos de tratamento de cáncer em mamìferos, método de redução do nìvel de p95 her2 em célula e método de diagnóstico
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
WO2007038792A2 (en) * 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
EP1913958B1 (en) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab
FR2904782B1 (fr) * 2006-08-11 2008-10-31 Delta Proteomics Soc Par Actio Co-colloides supramoleculaires obtenus a l'aide de systemes macrocycliques polyanioniques
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
EP2133433A1 (en) * 2008-06-09 2009-12-16 Centre Georges François Leclerc A method for predicting responsiveness to a treatment with an anti-HER2 antibody
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010061269A2 (en) * 2008-11-02 2010-06-03 Optimata Ltd. Improving cancer therapy by docetaxel and granulocyte colony-stimulating factor (g-csf)
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
KR20130000384A (ko) 2010-02-18 2013-01-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 뉴레귤린 길항제 및 암의 치료에서의 그의 용도
WO2011139172A1 (en) 2010-05-06 2011-11-10 Goran Milosavljevic Diterpene compounds with antineoplastic activities and pharmaceutical compositions comprising same
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
JP6109175B2 (ja) * 2011-09-01 2017-04-05 バスキュラー バイオジェニックス リミテッド 酸化リン脂質の製剤および剤形
CN102321175B (zh) * 2011-09-21 2013-08-07 天津胜发生物技术有限公司 针对乳腺癌Her2/new的纳米抗体或多肽
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
JP6998646B2 (ja) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
CN103102414B (zh) * 2013-02-04 2014-08-27 无锡傲锐东源生物科技有限公司 抗her2蛋白单克隆抗体及其用途
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
CN109966499A (zh) * 2019-04-25 2019-07-05 苏州大学 协同增效的抗乳腺癌转移药物组合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers

Also Published As

Publication number Publication date
CN1350464A (zh) 2002-05-22
EA200101064A1 (ru) 2002-04-25
AU777661B2 (en) 2004-10-28
CA2368369C (en) 2014-03-25
BR0009647A (pt) 2002-01-08
HK1046093B (zh) 2005-10-28
JP2012136535A (ja) 2012-07-19
DK1169059T3 (da) 2006-02-27
US6333348B1 (en) 2001-12-25
HUP0201459A3 (en) 2003-04-28
DE60023476T2 (de) 2006-07-06
HK1046093A1 (en) 2002-12-27
NO20014842D0 (no) 2001-10-04
CZ20013614A3 (cs) 2002-07-17
MXPA01010138A (es) 2003-07-14
NO332619B1 (no) 2012-11-19
JP2003512298A (ja) 2003-04-02
KR20020007358A (ko) 2002-01-26
EP1169059B1 (en) 2005-10-26
ES2248070T3 (es) 2006-03-16
EP1169059A1 (en) 2002-01-09
NZ515337A (en) 2003-10-31
ATE307608T1 (de) 2005-11-15
CN1191859C (zh) 2005-03-09
CA2368369A1 (en) 2000-10-19
ZA200107771B (en) 2002-09-20
HUP0201459A2 (en) 2002-09-28
WO2000061185A1 (en) 2000-10-19
DE60023476D1 (de) 2005-12-01
KR100695383B1 (ko) 2007-03-15
CZ296373B6 (cs) 2006-03-15
HU226672B1 (en) 2009-06-29
EA006097B1 (ru) 2005-08-25
NO20014842L (no) 2001-10-04
HK1043313A1 (zh) 2002-09-13
AU4332700A (en) 2000-11-14

Similar Documents

Publication Publication Date Title
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
TR200200472T2 (tr) Anti-Erb B2 antikorları ile tedavi için dozajlar
WO2002046477A3 (en) Endogenous retroviruses up-regulated in prostate cancer
BR0012195A (pt) Método para tratar câncer de próstata num ser humano, artigo de fabricação e uso de um anticorpo que liga erbb2
EP1383785A4 (en) RECOMBINANT, TUMOR-SPECIFIC ANTIBODIES AND THEIR USE
TNSN05300A1 (en) Treatment with anti-vegf antibodies
AR033157A1 (es) Uso de proteina alfa de activacion de los fibroblastos ("fapaalfa")bibh1 en el tratamiento del cancer
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
RU2008128244A (ru) Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
TR199802423T2 (tr) Konsantre antikor terkibi.
TR200001253T2 (tr) Tümöre özel antijenler
ATE364618T1 (de) Antikörper gegen das muc18-antigen
CY1109125T1 (el) Θεραπευτικα και διαγνωστικα anti-hsp 70 αντισωματα
MX9700534A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
WO1999029729A3 (en) Antagonists of neuropilin receptor function and use thereof
MXPA03008739A (es) Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores.
ATE407147T1 (de) Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein
TR199800270T1 (tr) Kanser hastaliklarinin ilerlemesini önlemede flukonazol kullanimi.
DK1235571T3 (da) Anvendelse af melatonin til behandling af androgenetisk eller diffus alopecia af feminin type
IL163900A (en) Antibody which binds to tpte for use in diagnosing, monitoring, preventing or treating cancer disease and pharmaceutical compositions comprising said antibody
TR200103786T2 (tr) Güğüs kanserinin tehisi ve imünoterapisi için bileşikler ve bunların kullanımı
TR200001040T2 (tr) Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı